Clinical Trial: Development of Patient Derived Xenografts (PDXs) and Analysis of Tyrosine Kinase Receptor Expression in Patients With Squamous Cell Head and Neck Cancer (HNSCC) to Study Resistance Mechanisms Induced by Standard Therapy

U.S., March 14 -- ClinicalTrials.gov registry received information related to the study (NCT07471009) titled 'Development of Patient Derived Xenografts (PDXs) and Analysis of Tyrosine Kinase Receptor Expression in Patients With Squamous Cell Head and Neck Cancer (HNSCC) to Study Resistance Mechanisms Induced by Standard Therapy' on March 10.

Brief Summary: Protocol TitleDevelopment of Patient-Derived Xenografts (PDXs) and analysis of tyrosine kinase receptor expression in patients with Head and Neck Squamous Cell Carcinoma (HNSCC) to study resistance mechanisms induced by standard therapy (SPAR).Brief SummaryThe SPAR study aims to better understand why some patients with head and neck squamous cell carcinoma (HNSCC) stop responding to stan...